Gray matter atrophy rate as a marker of disease progression in AD.

"Disclosure statement Dr. Fox has served on the scientific advisory boards of Alzheimer's Research Forum, Alzheimer's Society, and Alzheimer's Research Trust, and editorial boards of Alzheimer's Disease and Associated Disorders; Neurodegenerative Diseases, and BioMed, Central — Alzheimer's Research and Therapy. He holds a patent for QA Box that may accrue revenue. In the last 5 years his research group has received payment for consultancy or for conducting studies from Abbott Laboratories, Elan Pharmaceuticals, Eisai, Eli Lilly, GE Healthcare, IXICO, Lundbeck, Pfizer, Inc., Sanofi-Aventis, and Wyeth Pharmaceuticals. He receives research support from MRC (G0801306 [PI], G0601846 [PI]), NIH (U01 AG024904 [Coinvestigator] [sub contract]), Alzheimer Research Trust (ART/RF/2007/1 [PI]), NIHR (Senior Investigator) and EPSRC (GR/S48844/01 [PI]). The other authors report no conflicts of interest. The study was granted ethical approval by the National Hospital for Neurology and Neurosurgery and Institute of Neurology joint Research Ethics Committee, and subjects gave written informed consent."

"We thank the subjects who agreed to participate in the study, and their caregivers. VMA is grateful for the advice and assistance received from Josephine Barnes, Nicola Hobbs and Matthew Clarkson. This work was undertaken at UCL/UCLH who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme, and with support from the Alzheimer's Society. The Dementia Research Centre is an Alzheimer's Research Trust Coordinating Centre. VMA is supported by the MS Society of Great Britain and Northern Ireland. NCF is funded by the Medical Research Council (UK) and is a NIHR senior investigator. JMS is funded through the HEFCE/NHS Senior Lecturer Scheme."